CAR-macrophage: An extensive immune enhancer to fight cancer

Affiliations

¹ National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
² NHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550000, China.
³ Department of Basic Medical Sciences, Center for Stem Cell and Regenerative Medicine, and The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
⁴ National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: lining@cicams.ac.cn.

Shuhang Wang et al. EBioMedicine. 2022 Feb.

. 2022 Feb:76:103873.

doi: 10.1016/j.ebiom.2022.103873. Epub 2022 Feb 10.

¹ National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
² NHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550000, China.
³ Department of Basic Medical Sciences, Center for Stem Cell and Regenerative Medicine, and The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
⁴ National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: lining@cicams.ac.cn.

No abstract available

Keywords: Cancer; Chimeric antigen receptor; Immunity; Macrophage; Therapy.

Conflict of interest statement

Declaration of interests All authors declare no conflicts of interest.

1. Morrissey M.A., Williamson A.P., Steinbach A.M., et al. Chimeric antigen receptors that trigger phagocytosis. eLife. 2018;7:e36688. doi: 10.7554/eLife.36688. - DOI - PMC - PubMed
1. Zhang W., Liu L., Su H., et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121(10):837–845. doi: 10.1038/s41416-019-0578-3. - DOI - PMC - PubMed
1. Klichinsky M., Ruella M., Shestova O., et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–953. doi: 10.1038/s41587-020-0462-y. - DOI - PMC - PubMed
1. Zhang L., Tian L., Dai X., et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13(1):153. doi: 10.1186/s13045-020-00983-2. - DOI - PMC - PubMed
1. Kang M., Lee S.H., Kwon M., et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43) doi: 10.1002/adma.202103258. - DOI - PubMed